Oncology

Leading cancer research and clinical trials

Advancing Cancer Treatment

SXR Laboratories specializes in oncology clinical trials across all phases of drug development. We have extensive experience in solid tumors and hematologic malignancies, conducting trials for novel targeted therapies, immunotherapies, and combination treatments.

Our Expertise

Phase I-III oncology trials
Immunotherapy and checkpoint inhibitors
Targeted molecular therapies
CAR-T cell therapy trials
Biomarker-driven studies
Supportive care research

Foundational Technologies & Key Targets

Cell Therapy Platforms
CAR-T (Chimeric Antigen Receptor T-cell): Engineering patient T-cells to recognize and eliminate cancer cells, particularly effective in blood cancers targeting CD19 and BCMA antigens.
TCR-T (T-cell Receptor T-cell): Utilizing modified T-cell receptors for more specific targeting of intracellular tumor antigens.
TILs (Tumor-Infiltrating Lymphocytes): Harvesting, expanding, and reinfusing immune cells directly from patient tumors for personalized immunotherapy.

Molecular Targets

Key targets include EGFR, ALK, BRAF, HER2 for targeted therapy; PD-1/PD-L1, CTLA-4 for immune checkpoint inhibition; and CD19, BCMA for CAR-T therapy.

Therapeutic Approaches

Immuno-oncology (IO): Harnessing the immune system through checkpoint inhibitors, CAR-T cells, and TILs. Targeted Therapy: Small molecules and biologics interfering with specific molecular pathways (Kinase Inhibitors, PARP Inhibitors). Angiogenesis Inhibitors: Blocking tumor blood vessel formation. Gene Therapy: Using CRISPR to enhance CAR-T potency or disrupt immune evasion mechanisms.

Comprehensive Support

Our oncology program includes specialized tumor boards, advanced imaging capabilities, and comprehensive biomarker analysis to support precision medicine approaches in cancer treatment.

Integrated Research Excellence

Our oncology program’s success stems from seamless integration of specialized services. Clinical Trials Management oversees the complex coordination of multi-phase cancer studies, while Data Management ensures precise capture of critical biomarker and efficacy data. Biostatistics teams apply advanced survival analysis and adaptive designs to maximize trial efficiency. Regulatory Affairs navigates oncology-specific pathways including breakthrough therapy designations, and Medical Writing crafts compelling clinical study reports that communicate complex oncology findings. Quality Assurance maintains the highest standards throughout, ensuring data integrity for life-saving cancer therapies.